Basilea Pharmaceutica Reaches Milestone with Strong European Sales of Cresemba®

Basilea Pharmaceutica Reaches Milestone with Strong European Sales of Cresemba®

(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone follows several similar payments from Cresemba’s sales in Asia Pacific and China. The drug is now approved in over 70 countries and reported global sales of USD 489 million in the past year, reflecting a 24 percent growth.

(PRESS RELEASE) ALLSCHWIL, 6-Sep-2024— /EuropaWire/ — Basilea Pharmaceutica Ltd (SIX: BSLN), a leading biopharmaceutical firm specializing in treatments for severe bacterial and fungal infections, has achieved a significant milestone. The company announced today that its antifungal drug, Cresemba® (isavuconazole), has reached impressive sales figures in Europe, triggering a USD 25 million milestone payment from its partner Pfizer.

The milestone payment underscores the strong performance of Cresemba in the European market, reflecting its critical role in addressing life-threatening invasive mold infections. Basilea’s CEO, David Veitch, expressed his satisfaction with the news, noting, “We are thrilled to see Cresemba’s continued success and its positive impact on patient care. This milestone payment highlights the drug’s ongoing growth and recognition in the global market.”

The license agreement between Basilea and Pfizer includes Europe (excluding the Nordic countries), 16 countries in the Asia Pacific region, and China. This year alone, Basilea has announced several milestone payments triggered by Cresemba’s sales in Asia Pacific and China, demonstrating the drug’s expanding success.

Cresemba is now approved and marketed in over 70 countries, including major markets such as the United States and most EU member states. The latest data indicates that global sales of Cresemba reached USD 489 million from April 2023 to March 2024, marking a notable 24 percent increase compared to the previous year.

Basilea continues to focus on advancing its portfolio and delivering innovative treatments to meet the needs of patients worldwide.

About isavuconazole (Cresemba®)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®. Basilea has entered into several license and distribution agreements for isavuconazole covering approximately 115 countries. In the 27 European Union member states, as well as in Iceland, Liechtenstein and Norway, isavuconazole is approved for patients aged from 1 year of age and older for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.2 Isavuconazole is also approved in the United States (US) and several additional countries in Europe and beyond, including the U.K., China and Japan.3 It has orphan drug designation in the US, Europe and Australia for its approved indications.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

1. IQVIA Analytics Link, March 2024. In-market sales reported as moving annual total (MAT) in US dollar.
2. European Public Assessment Report (EPAR) Cresemba, not yet updated to reflect recent extension to pediatric patients: www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: September 6, 2024]
3. The registration status and approved indications may vary from country to country.

Media Contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Phone: +41 61 606 1102
E-mail: media_relations@basilea.com
investor_relations@basilea.com

SOURCE: Basilea Pharmaceutica Ltd